Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5250_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Preface
- •Contents
- •1.1.2.5 Priming (Guiding) Transcranial Magnetic Stimulation (pTMS)
- •1.1.2.6 Synchronized Transcranial Magnetic Stimulation (sTMS)
- •1.1.2.8 Magnetic Seizure Therapy (MST)
- •1.2.1 Treatment Procedures
- •1.2.2 TMS Treatment Precautions
- •1.2.2.1 Seizure Risk
- •1.2.2.3 Other Precautions
- •1.3.1.1 Membrane Potential Alterations
- •1.4 Effect Factors
- •1.4.1 Stimulation Frequency
- •About the Editors
- •1: Transcranial Magnetic Stimulation
- •1.1 Introduction
- •1.1.2.1 Repetitive Transcranial Magnetic Stimulation (rTMS)
- •1.1.2.2 Prolonged Intermittent Theta Burst Stimulation (piTBS)
- •1.1.2.4 Deep Transcranial Magnetic Stimulation (dTMS)
- •1.4.2 Stimulation Intensity
- •1.4.3 Pulse Duration
- •1.4.5 Interstimulus Interval
- •1.5 Conclusion
- •References
- •2: Transcranial Direct Current Stimulation
- •2.1 Introduction
- •2.3.3 Nonneuronal Mechanisms
- •2.3.4 Others
- •2.4 Effect Factors
- •2.4.1 Stimulus Polarity
- •2.4.2 Duration
- •2.4.3 Current Intensity
- •2.4.4 Others
- •2.5 Summary and Outlook
- •References
- •3: Major Depressive Disorder
- •3.1 Introduction
- •3.2 TMS
- •3.2.1 rTMS
- •3.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.2 Deep TMS
- •3.2.2.1 Efficacy
- •3.2.2.2 Safety
- •3.2.2.3 Treatment Regimen
- •3.2.2.4 Clinical Recommendations
- •3.2.3 Priming rTMS
- •3.2.3.1 Efficacy
- •3.2.3.2 Safety
- •3.2.3.3 Treatment Regimen
- •3.2.3.4 Clinical Recommendations
- •3.2.4 Synchronized rTMS
- •3.2.4.1 Efficacy
- •3.2.4.2 Safety
- •3.2.4.3 Treatment Regimen
- •3.2.4.4 Clinical Recommendations
- •3.2.5 TBS
- •3.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.5.3 Continuous TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •3.2.6 Magnetic Seizure Therapy (MST)
- •3.2.6.1 Efficacy
- •3.2.6.2 Safety
- •3.2.6.3 Treatment Regimen
- •3.2.6.4 Clinical Recommendations
- •3.3 tDCS
- •3.3.1 Conventional tDCS
- •3.3.1.1 Efficacy
- •3.3.1.3 Treatment Regimen
- •3.3.1.4 Clinical Recommendations
- •3.3.2 HD-tDCS
- •3.3.2.1 Efficacy
- •3.3.2.2 Safety
- •3.3.2.3 Treatment Regimen
- •3.3.2.4 Clinical Recommendations
- •3.4 TMS Vs. tDCS
- •3.4.1 Efficacy
- •3.4.2 Safety
- •3.5 Conclusion
- •References
- •3.3.1.2 Safety
- •4: Bipolar Disorder
- •4.1 Introduction
- •4.2 TMS
- •4.2.1 rTMS
- •4.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.2 Deep TMS
- •4.2.2.1 Efficacy
- •4.2.2.2 Safety
- •4.2.2.3 Treatment Regimen
- •4.2.2.4 Clinical Recommendations
- •4.2.3 Priming TMS
- •4.2.3.1 Efficacy
- •4.2.3.2 Safety
- •4.2.3.3 Treatment Regimen
- •4.2.3.4 Clinical Recommendations
- •4.2.4 Synchronized TMS
- •4.2.4.1 Efficacy
- •4.2.4.2 Safety
- •4.2.4.3 Treatment Regimen
- •4.2.4.4 Clinical Recommendations
- •4.2.5 TBS
- •4.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.5.3 Continuous TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •4.2.6 MST
- •4.2.6.1 Efficacy
- •4.2.6.2 Safety
- •4.2.6.3 Treatment Regimen
- •4.2.6.4 Clinical Recommendations
- •4.3 tDCS
- •4.3.1 Conventional tDCS
- •4.3.1.1 Efficacy
- •4.3.1.2 Safety
- •4.3.1.3 Treatment Regimen
- •4.3.1.4 Clinical Recommendations
- •4.3.2 HD-tDCS
- •4.3.2.1 Efficacy
- •4.3.2.2 Safety
- •4.3.2.3 Treatment Regimen
- •4.3.2.4 Clinical Recommendations
- •4.4 TMS vs. tDCS
- •4.4.1 Efficacy
- •4.4.2 Safety
- •4.5 Conclusion
- •References
- •5: Schizophrenia
- •5.1 Schizophrenia
- •5.2 TMS
- •5.2.1 rTMS
- •5.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.2 Deep TMS
- •5.2.2.1 Efficacy
- •5.2.2.2 Safety
- •5.2.2.3 Treatment Regimen
- •5.2.2.4 Clinical Recommendations
- •5.2.3 Priming TMS
- •5.2.3.1 Efficacy
- •5.2.3.2 Safety
- •5.2.3.3 Treatment Regimen
- •5.2.3.4 Clinical Recommendations
- •5.2.4 Synchronized TMS
- •5.2.4.1 Efficacy
- •5.2.4.2 Safety
- •5.2.4.3 Treatment Regimen
- •5.2.4.4 Clinical Recommendations
- •5.2.5 TBS
- •5.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •5.2.6 MST
- •5.2.6.1 Efficacy
- •5.2.6.2 Safety
- •5.2.6.3 Treatment Regimen
- •5.2.6.4 Clinical Recommendations
- •5.3 tDCS
- •5.3.1 Conventional tDCS
- •5.3.1.1 Efficacy
- •5.3.1.2 Safety
- •5.3.1.3 Treatment Regimen
- •5.3.1.4 Clinical Recommendations
- •5.3.2 HD-tDCS
- •5.3.2.1 Efficacy
- •5.3.2.2 Safety
- •5.3.2.3 Treatment Regimen
- •5.3.2.4 Clinical Recommendations
- •5.4 TMS vs. tDCS
- •5.4.1 Efficacy
- •5.4.2 Safety
- •5.5 Conclusion
- •References
- •6: Addictive Disorders
- •6.1 Addictive Disorders
- •6.2 TMS
- •6.2.1 rTMS
- •6.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •6.2.1.2 Bilateral rTMS
- •6.2.1.3 Accelerated rTMS
- •6.2.2 Deep TMS
- •6.2.3 Priming TMS
- •6.2.4 Synchronized TMS
- •6.2.5 TBS
- •6.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •6.2.5.2 Accelerated iTBS
- •6.2.5.3 Continuous TBS
- •6.2.5.4 Bilateral TBS
- •6.2.6 MST
- •6.3 tDCS
- •6.3.1 Conventional tDCS
- •6.3.1.1 Efficacy
- •6.3.1.2 Safety
- •6.3.1.3 Treatment Regimen
- •6.3.1.4 Clinical Recommendations
- •6.3.2 HD-tDCS
- •6.4 TMS vs. tDCS
- •6.4.1 Efficacy
- •6.4.2 Safety
- •6.5 Conclusion
- •References
- •7: Obsessive-Compulsive Disorder
- •7.1 Introduction
- •7.2 TMS
- •7.2.1 rTMS
- •7.2.1.1 Unilateral rTMS
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.2 Deep TMS
- •7.2.2.1 Efficacy
- •7.2.2.2 Safety
- •7.2.2.3 Treatment Regimen
- •7.2.2.4 Clinical Recommendations
- •7.2.3 Priming TMS
- •7.2.3.1 Efficacy
- •7.2.3.2 Safety
- •7.2.3.3 Treatment Regimen
- •7.2.3.4 Clinical Recommendations
- •7.2.4 Synchronized TMS
- •7.2.4.1 Efficacy
- •7.2.4.2 Safety
- •7.2.4.3 Treatment Regimen
- •7.2.4.4 Clinical Recommendations
- •7.2.5 TBS
- •7.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •7.2.6 MST
- •7.2.6.1 Safety
- •7.2.6.2 Treatment Regimen
- •7.2.6.3 Clinical Recommendations
- •7.3 tDCS
- •7.3.1 Conventional tDCS
- •7.3.1.1 Efficacy
- •7.3.1.2 Safety
- •7.3.1.3 Treatment Regimen
- •7.3.1.4 Clinical Recommendations
- •7.3.2 HD-tDCS
- •7.3.2.1 Efficacy
- •7.3.2.2 Safety
- •7.3.2.3 Treatment Regimen
- •7.3.2.4 Clinical Recommendations
- •7.4 TMS vs. tDCS
- •7.4.1 Efficacy
- •7.4.2 Safety
- •7.5 Conclusion
- •References
- •8: Attention Deficit Hyperactivity Disorder
- •8.1 ADHD
- •8.1.2 Therapeutic Method
- •8.2 TMS
- •8.2.1 Single-Pulse TMS (spTMS)
- •8.2.1.1 Efficacy
- •8.2.1.2 Safety
- •8.2.1.3 Treatment Regimen
- •8.2.1.4 Clinical Recommendations
- •8.2.2 Paired-Pulse TMS (ppTMS)
- •8.2.2.1 Efficacy
- •8.2.2.2 Safety
- •8.2.2.3 Treatment Regimen
- •8.2.2.4 Clinical Recommendations
- •8.2.3 rTMS
- •8.2.3.1 Low-Frequency rTMS (LF-rTMS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.2.3.2 High-Frequency rTMS (HF-rTMS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.2.4 TBS
- •8.2.4.1 Intermittent TBS (iTBS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.2.4.2 Continuous iTBS (cTBS)
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •8.3 tDCS
- •8.3.1 Conventional tDCS
- •8.3.1.1 Efficacy
- •8.3.1.2 Safety
- •8.3.1.3 Treatment Regimen
- •8.3.1.4 Clinical Recommendations
- •8.3.2.1 Efficacy
- •8.3.2.2 Safety
- •8.3.2.3 Treatment Regimen
- •8.3.2.4 Clinical Recommendations
- •8.4 TMS vs. tDCS
- •8.4.1 Efficacy
- •8.4.2 Safety
- •8.5 Conclusion
- •References
- •9: Autism Spectrum Disorder
- •9.1 Introduction
- •9.2 rTMS
- •9.2.1 Unilateral rTMS
- •9.2.1.1 Efficacy
- •9.2.1.2 Safety
- •9.2.1.3 Treatment Regimen
- •9.2.1.4 Clinical Recommendations
- •9.2.1.5 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.1.6 Accelerated rTMS
- •9.2.2 Deep TMS
- •9.2.2.1 Efficacy
- •9.2.2.2 Safety
- •9.2.2.3 Treatment Regimen
- •9.2.2.4 Clinical Recommendations
- •9.2.3 Priming TMS
- •9.2.4 Synchronized TMS
- •9.2.5 TBS
- •9.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.5.2 Accelerated iTBS
- •9.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •9.2.6 MST
- •9.3 tDCS
- •9.3.1 Conventional tDCS
- •9.3.1.1 Efficacy
- •9.3.1.2 Safety
- •9.3.1.3 Treatment Regimen
- •9.3.1.4 Clinical Recommendations
- •9.3.2 HD-tDCS
- •9.3.2.1 Efficacy
- •9.3.2.2 Safety
- •9.3.2.3 Treatment Regimen
- •9.3.2.4 Clinical Recommendations
- •9.4 TMS Vs. tDCS
- •9.4.1 Efficacy
- •9.4.1.1 Cognitive Effects
- •9.4.1.3 Biological Effects
- •9.4.2 Safety
- •9.5 Conclusion
- •References
- •10: Anxiety Disorder
- •10.1 Introduction
- •10.2 TMS
- •10.2.1 rTMS
- •10.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.2 Deep TMS
- •10.2.2.1 Efficacy
- •10.2.2.2 Safety
- •10.2.2.3 Treatment Regimen
- •10.2.2.4 Clinical Recommendations
- •10.2.3 Priming TMS
- •10.2.3.1 Efficacy
- •10.2.3.2 Safety
- •10.2.3.3 Treatment Regimen
- •10.2.3.4 Clinical Recommendations
- •10.2.4 Synchronized TMS
- •10.2.4.1 Efficacy
- •10.2.4.2 Safety
- •10.2.4.3 Treatment Regimen
- •10.2.4.4 Clinical Recommendations
- •10.2.5 TBS
- •10.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.5.3 Continuation TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.5.4 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •10.2.6 Magnetic Seizure Therapy (MST)
- •10.3 tDCS
- •10.3.1 Conventional tDCS
- •10.3.1.1 Efficacy
- •10.3.1.2 Safety
- •10.3.1.3 Treatment Regimen
- •10.3.1.4 Clinical Recommendations
- •10.3.2 HD-tDCS
- •10.3.2.1 Efficacy
- •10.3.2.2 Safety
- •10.3.2.3 Clinical Recommendations
- •10.4 TMS versus tDCS
- •10.4.1 Efficacy
- •10.4.2 Safety
- •10.5 Conclusion
- •References
- •11: Post-traumatic Stress Disorder
- •11.1 Introduction
- •11.2 TMS
- •11.2.1 rTMS
- •11.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.1.3 Accelerated rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.2 Deep TMS
- •11.2.2.1 Efficacy
- •11.2.2.2 Safety
- •11.2.2.3 Treatment Regimen
- •11.2.2.4 Clinical Recommendations
- •11.2.3 Priming TMS
- •11.2.3.1 Efficacy
- •11.2.3.2 Safety
- •11.2.3.3 Treatment Regimen
- •11.2.3.4 Clinical Recommendations
- •11.2.4 Synchronized TMS
- •11.2.4.1 Efficacy
- •11.2.4.2 Safety
- •11.2.4.3 Treatment Regimen
- •11.2.4.4 Clinical Recommendations
- •11.2.5 TBS
- •11.2.5.1 iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.5.2 Accelerated iTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.5.3 Bilateral TBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •11.2.6 MST
- •11.2.6.1 Efficacy
- •11.2.6.2 Safety
- •11.2.6.3 Treatment Regimen
- •11.2.6.4 Clinical Recommendations
- •11.3 tDCS
- •11.3.1 Conventional tDCS
- •11.3.1.1 Efficacy
- •11.3.1.2 Safety
- •11.3.1.3 Treatment Regimen
- •11.3.1.4 Clinical Recommendations
- •11.3.2 HD-tDCS
- •11.3.2.1 Efficacy
- •11.3.2.2 Safety
- •11.3.2.3 Treatment Regimen
- •11.3.2.4 Clinical Recommendations
- •11.4 TMS vs. tDCS
- •11.4.1 Efficacy
- •11.4.2 Safety
- •11.5 ECT
- •11.5.1 Efficacy
- •11.5.2 Safety
- •11.5.3 Treatment Regimen
- •11.5.4 Clinical Recommendations
- •11.6 Conclusion
- •References
- •12: Sleep Disorders
- •12.1 Introduction
- •12.2 TMS
- •12.2.1 rTMS
- •12.2.1.1 Unilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •12.2.1.2 Bilateral rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •12.2.1.3 Accelerated rTMS
- •12.2.2 Deep TMS
- •12.2.3 Priming TMS
- •12.2.4 Synchronised TMS
- •12.2.5 TBS
- •12.2.5.1 iTBS
- •12.2.5.2 Accelerated iTBS
- •12.2.5.3 cTBS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •12.2.5.4 Bilateral TBS
- •12.2.6 MST
- •12.3 tDCS
- •12.3.1 Efficacy
- •12.3.2 Safety
- •12.3.3 Treatment Regimen
- •12.3.4 Clinical Recommendations
- •12.4 TMS Combined tDCS
- •12.4.1 Efficacy
- •12.4.2 Safety
- •12.5 Conclusion
- •References
- •13: Neurocognitive Disorders
- •13.1 Introduction
- •13.2 TMS
- •13.2.1 TMS
- •13.2.1.1 Conventional rTMS
- •Efficacy
- •Safety
- •Treatment Regimen
- •Clinical Recommendations
- •13.2.1.2 Accelerated rTMS
- •13.2.2 Deep TMS
- •13.2.2.1 Efficacy
- •13.2.2.2 Safety
- •13.2.2.3 Treatment Regimen
- •13.2.2.4 Clinical Recommendations
- •13.2.3 Priming TMS
- •13.2.4 Synchronized TMS
- •13.2.5 iTBS
- •13.2.5.1 Efficacy
- •13.2.5.2 Safety
- •13.2.5.3 Treatment Regimen
- •13.2.5.4 Clinical Recommendations
- •13.2.6 Magnetic Seizure Therapy
- •13.3.1 Conventional tDCS
- •13.3.1.1 Efficacy
- •13.3.1.2 Safety
- •13.3.1.3 Treatment Regimen
- •13.3.1.4 Clinical Recommendations
- •13.3.2 HD-tDCS
- •13.3.2.1 Efficacy
- •13.3.2.2 Safety
- •13.3.2.3 Treatment Regimen
- •13.3.2.4 Clinical Recommendations
- •13.4 TMS vs. tDCS
- •13.4.1 Efficacy
- •13.4.2 Safety
- •13.5 Conclusion
- •References

About the Editors
Wei Zheng is an Associate Professor in the
Department of Psychiatry, the Afliated Brain
Hospital, Guangzhou Medical University, Guangzhou,
China. He completed resident psychiatrist training in
the Afliated Brain Hospital, Guangzhou Medical
University, China, and obtained PhD degree in
Guangzhou Medical University. His research focuses
on neuroregulatory techniques related research. He
has authored or co-authored over 190 papers in international (SCI) journals. He is serving as one of the
Editor-in-Chief of Alpha Psychiatry (IF=3.5) at present. He was awarded the title of Top 2% Global
Scientists in 2023 and 2024. His team has made some
advances in antipsychotic-induced hyperproteinemia
and weight gain, ketamine, and neuroregulatory techniques including TMS, tDCS, tACS, and ECT for
treatment-resistant depression.
Yuping Ning is a Professor at the Department of
Psychiatry, the Afliated Brain Hospital, Guangzhou
Medical University, Guangzhou, China. She is the
director of the Afliated Brain Hospital, Guangzhou
Medical University, PRC.She is a Professor in neuropsychiatry and supervisor of PhD students. She holds
some positions such as member of Chinese Society
of Psychiatry, Chairman of Guangdong Society of
Psychiatry, member of standing committee of
Guangdong Society of Neurology, etc. From 1986 to
1992, she educated in XiangYa Medical College and
got MD degree there. From 1992 to 1997, she practiced psychiatry in Guangzhou Brain Hospital. From
1997 to 2003, she practiced and pursued her PhD in the
Department of Neurology, Sun Yat-Sen Medical
xi

xii
About the Editors
University. Her research interests are in neurodegenerative diseases (AD and PD) and depression. As a visiting scholar, she performed genetic study in Parkinson
disease in Juntendo University, Japan. She has published 200 papers so far.

Transcranial Magnetic Stimulation
YongLiu andShaohuaHu
Abstract
Psychiatric disorders have become a major global health challenge, and tradi-
tional treatments often have limitations. Transcranial magnetic stimulation
(TMS), a noninvasive neuromodulation therapy, has shown signicant potential
in clinical settings. This chapter discusses the fundamental principles of TMS,
common modalities such as repetitive TMS (rTMS), intermittent theta burst
stimulation (iTBS), and deep TMS, as well as treatment procedures, precautions,
and underlying mechanisms. TMS modulates neuronal excitability, synaptic
plasticity, and the functional connectivity of brain circuits, with variations in
stimulation frequency, intensity, and pulse parameters signicantly inuencing
its outcomes. While TMS has proven effective in treating resistant psychiatric
conditions like depression with fewer side effects, further research is needed to
optimize its mechanisms, personalize treatment protocols, and enhance equip-
ment. This chapter aims to provide psychiatrists, neuroscientists, and other medi-
cal professionals with a comprehensive understanding of TMS, promoting its
advancement and broader application in psychiatric treatment.
1
Keywords
Transcranial magnetic stimulation · Noninvasive neuromodulation · Psychiatric
disorders
Y. Liu · S. Hu (*)
Department of Psychiatry, the First Afliated Hospital, Zhejiang University School
of Medicine, Hangzhou, China
The Zhejiang Key Laboratory of Precision Psychiatry, Hangzhou, China
e-mail: drliuyong@zju.edu.cn; dorhushaohua@zju.edu.cn
© The Author(s), under exclusive license to Springer Nature Singapore Pte
Ltd. 2025
W. Zheng, Y. Ning (eds.), TMS and tDCS for Psychiatric Disorders,
https://doi.org/10.1007/978-981-96-8504-2_1
1

2
Y. Liu and S. Hu
Abbreviations
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
aTMS accelerated repetitive transcranial magnetic stimulation
cTBS continuous theta burst stimulation
CaMKII calcium/calmodulin-dependent protein kinase II
dTMS deep transcranial magnetic stimulation
DLPFC dorsolateral prefrontal cortex
ECT electroconvulsive therapy
GABA γ-aminobutyric acid
iTBS intermittent theta burst stimulation
LTP long-term potentiation
LTD long-term depression
MST magnetic seizure therapy
NMDA N-methyl-D-aspartate receptor
piTBS prolonged intermittent theta burst stimulation
pTMS priming (guiding) transcranial magnetic stimulation
rTMS repetitive transcranial magnetic stimulation
sTMS synchronized transcranial magnetic stimulation
SAINT Stanford Accelerated Intelligent Neuromodulation Therapy
TMS transcranial magnetic stimulation
TBS theta burst stimulation
Nav voltage-gated sodium channels
1.1 Introduction
Psychiatric disorders have become a signicant global health challenge, with profound implications for public health. According to the World Health Organization
(WHO), approximately 970 million people worldwide were living with a mental
disorder in 2019. The prevalence of psychiatric conditions has been steadily increasing, with an estimated 25% rise in the number of affected individuals between 2000
and 2019 [1]. This growing burden not only affects the well-being of patients but
also places immense strain on families and healthcare systems, highlighting the
societal and economic impact of mental health disorders.
Traditional treatment methods for psychiatric disorders, including pharmacotherapy and psychotherapy, offer symptomatic relief but have notable limitations.
Pharmacological treatments are often associated with side effects, and their efcacy
may be insufcient for some patients. While psychotherapy can be benecial, it
tends to be time-consuming and requires a high level of patient adherence. In this
context, transcranial magnetic stimulation (TMS), an emerging noninvasive neuromodulation therapy, has gained signicant attention as a promising alternative.
TMS operates on the principles of electromagnetic induction, using a coil placed
on the scalp to generate a magnetic eld that penetrates the skull and induces weak
electrical currents in the cerebral cortex. This electrical activity modulates neuronal
activity in specic brain regions, offering a means to inuence dysfunctional neural

1 Transcranial Magnetic Stimulation
3
circuits. Recent studies have demonstrated the signicant potential of TMS in treating psychiatric disorders [2–4]. Its noninvasive nature and ability to precisely target
brain regions make it an attractive alternative to traditional pharmacological treatments, especially for patients who are resistant to medication or experience intolerable side effects. With ongoing advancements in TMS technology and a growing
body of clinical evidence, TMS is emerging as a valuable tool in the management of
psychiatric disorders, offering hope for patients with conditions that are difcult to
treat by conventional means.
In this chapter, our goal is to provide a comprehensive exploration of TMS in
psychiatric treatment. This includes an overview of the fundamental principles
and common parameters of TMS, as well as advanced techniques and approaches
used in clinical practice. We will also discuss treatment procedures, key precautions, underlying mechanisms, and factors inuencing the efcacy of
TMS.Through this examination, we aim to offer a thorough understanding of
how TMS is utilized to address various psychiatric conditions and optimize
therapeutic outcomes.
Additionally, the chapter explores the latest evidence-based ndings and future
directions for TMS research. By integrating a wealth of clinical data and cuttingedge research, this work serves as an authoritative and practical resource for psychiatrists, neuroscientists, and other medical professionals. It is intended to promote
the further development of TMS in psychiatry and improve the quality of life and
treatment outcomes for patients suffering from mental disorders.
1.1.1 Fundamentals ofTMS
TMS modulates neural activity in the brain based on the principles of electromagnetic induction. When a pulsed current is passed through a coil placed on the scalp,
it generates a time-varying magnetic eld in accordance with Ampère’s law. This
magnetic eld can penetrate the skull, despite its electrical impedance and magnetic
permeability. The magnetic eld strength of TMS, typically in the range of 1–2Tesla,
is sufcient to reach the cerebral cortex.
According to Faraday’s law of electromagnetic induction, the changing magnetic
eld induces an electric eld in the conductive tissue of the cerebral cortex. This
electric eld, in turn, generates an induced current in the neurons. When the induced
current affects the neurons, it alters their membrane potential. If the membrane
potential reaches the depolarization threshold, voltage-gated sodium channels open,
allowing sodium ions to inux and triggering an action potential, thereby increasing
neuronal excitability. Conversely, if the membrane potential is hyperpolarized, neuronal excitability is reduced [5].
1.1.2 TMS andIts Advanced Approaches
In recent years, TMS has given rise to a variety of advanced application modalities,
which mainly include the following.

4
Y. Liu and S. Hu
1.1.2.1 Repetitive Transcranial Magnetic Stimulation (rTMS)
Repetitive transcranial magnetic stimulation is a common derivative form of TMS.It
exerts regulatory effects on brain neural activities by repetitively applying magnetic
stimulation to the brain at specic frequencies and intensities. The frequency and
intensity settings of rTMS are crucial in determining its impact on neuronal excitability. For example, the frequency and intensity can be adjusted according to the
specic treatment needs and the patient’s condition [6].
1.1.2.2 Prolonged Intermittent Theta Burst Stimulation (piTBS)
Prolonged intermittent theta burst stimulation represents a special stimulation paradigm. It is based on the principle of theta burst stimulation (TBS), which involves
pulse-train stimulation at a theta wave frequency (in the range of 4–7Hz). Moreover,
piTBS further extends the stimulation duration based on intermittent TBS.From a
neurophysiological perspective, this stimulation modality exhibits potential advantages in inducing brain plasticity. It can more effectively modulate the connection
strength between brain neurons [7].
1.1.2.3 Accelerated Repetitive Transcranial Magnetic
Stimulation (aTMS)
Accelerated repetitive transcranial magnetic stimulation is achieved by optimizing relevant parameters such as stimulation frequency. Through this optimization, a greater
number of stimulation pulses can be delivered within a relatively shorter time frame.
This accelerated stimulation paradigm can effectively reduce the treatment course while
ensuring the attainment of the expected therapeutic efcacy [8]. For patient populations
who urgently need rapid symptom improvement or have difculties in complying with
long-term treatment, aTMS represents a more appropriate option. However, it should be
noted that this stimulation method requires relatively high-performance equipment and
precise control of stimulation parameters.
1.1.2.4 Deep Transcranial Magnetic Stimulation (dTMS)
Deep transcranial magnetic stimulation has the capacity to generate a stronger magnetic eld, enabling it to penetrate deeper into brain tissues. The enhanced magnetic
eld strength of dTMS is achieved through specic coil designs and engineering
optimizations [9]. These modications allow for a more focused and intense magnetic eld that can overcome the attenuation and scattering effects as the magnetic
eld penetrates the overlying brain layers and skull. Studies have demonstrated that
dTMS can have differential effects on neural circuits within deeper brain regions,
potentially modulating neurotransmitter release and synaptic plasticity in a distinct
manner compared to supercial TMS [10].
1.1.2.5 Priming (Guiding) Transcranial Magnetic Stimulation (pTMS)
Priming (guiding) transcranial magnetic stimulation likely utilizes an initial application of a weak or specic patterned magnetic stimulation to “prime” the neural
response mechanisms in the brain, thereby creating favorable conditions for subsequent more effective stimulation or neuromodulation procedures.

1 Transcranial Magnetic Stimulation
5
Mechanistically, it serves as a pretreatment approach. By altering the state of
neural excitability in specic local brain regions, it enables the subsequent therapeutic magnetic stimulation to act more efciently. It is analogous to providing a
“guiding signal” to the brain, guiding it into a state that is more receptive to the
main stimulation. Furthermore, research has suggested that pTMS-induced priming can lead to changes in synaptic efcacy and neuronal ring patterns, which
may enhance the overall therapeutic efcacy in neurological and psychiatric disorders [11, 12].
1.1.2.6 Synchronized Transcranial Magnetic Stimulation (sTMS)
Synchronized transcranial magnetic stimulation (sTMS) involves the synchronization
of magnetic stimulation with the natural rhythms of the brain (such as brainwaves).
From the perspective of the precision of neuromodulation, this synchronized stimulation modality can more precisely target the temporal windows of brain neural activity,
thereby enhancing the stimulation effect [13]. Additionally, it may potentially enhance
the treatment efcacy for cognitive dysfunction. Evidence has shown that sTMS synchronized with specic brain rhythms can modulate the synchronization and coherence of neural networks, leading to improved cognitive performance and potentially
therapeutic benets in patients with cognitive impairments [14].
1.1.2.7 Various Forms ofTheta Burst Stimulation (TBS)
1. Intermittent TBS (iTBS): This stimulation modality intermittently applies pulse
train stimulation at theta wave frequencies. From the perspective of neuroplasticity, iTBS can modulate long-term potentiation (LTP) or long-term depression
(LTD) effects in brain neurons and holds signicant application value in research
and treatment related to neuroplasticity such as learning and memory. In a recent
study, patients who received Stanford Accelerated Intelligent Neuromodulation
Therapy (SAINT), potentially with an iTBS-based protocol, exhibited signicant improvements in depressive symptoms in a shorter time frame compared to
traditional rTMS protocols [15].
2. Continuous TBS (cTBS): Unlike intermittent TBS, cTBS continuously applies
pulse train stimulation at theta wave frequencies. In terms of its neuromodulatory effects, it generally exerts an inhibitory inuence on brain activity and may
hold potential for treating conditions such as treatment-resistant depression and
suicidal ideation [16].
3. Bilateral TBS: Bilateral theta burst stimulation is an advanced form of TMS that
applies theta burst protocols to both the left and right dorsolateral prefrontal
cortex (DLPFC). It involves the simultaneous or sequential delivery of intermittent or continuous theta burst stimulation, which modulates neuronal excitability
and functional connectivity in these key brain regions. Bilateral TBS has shown
promising therapeutic potential in treating mood disorders, such as depression,
by enhancing neuroplasticity and restoring balance in dysregulated neural circuits. As a noninvasive neuromodulation technique, it offers a novel alternative
to traditional pharmacological interventions, particularly for patients with treatment-resistant conditions [17, 18].

6
Y. Liu and S. Hu
1.1.2.8 Magnetic Seizure Therapy (MST)
Magnetic seizure therapy is a relatively high-intensity magnetic stimulation method
that can induce a seizure-like response in the brain similar to that in electroconvulsive therapy (ECT). However, compared with ECT, MST has better spatial selectivity. That is, by adjusting the location and parameters of magnetic stimulation, the
brain area of seizure onset can be more precisely controlled. Therefore, in treating
severe mental diseases such as treatment-resistant depression, MST can be used as
an alternative to ECT to improve patients’ symptoms by inducing large-scale
changes in brain neural activity [19].
1.1.3 Common Parameters ofTMS
TMS involves several key parameters that determine its effects on neural activity.
Stimulation frequency is a crucial factor. High-frequency TMS (>1Hz) typically
increases neuronal excitability and may induce long-term potentiation (LTP)-like
effects, while low-frequency TMS (<1Hz) usually decreases excitability, similar to
long-term depression (LTD) mechanisms. Intensity, measured in percentage of the
maximum stimulator output, inuences the depth and extent of neural activation.
Pulse width, which is the duration of each individual magnetic pulse, affects the
energy delivered and the resulting electric eld in the brain. The number of pulses
per session and the total number of sessions over a treatment course also play signicant roles in modulating neural plasticity and achieving therapeutic outcomes.
Additionally, the coil design, such as gure-of-eight or circular, determines the
focality and distribution of the magnetic eld, thereby impacting the specic brain
regions targeted. Precise control and optimization of these common parameters are
essential for both research applications and clinical effectiveness of TMS.
1.2 Treatment Procedures andPrecautions
1.2.1 Treatment Procedures
Pretreatment preparation includes gathering the patient’s medical history, conducting physical and neurological exams, and obtaining informed consent after explaining the TMS process, risks, and discomforts. Patient positioning is essential, with
the patient sitting comfortably, ensuring proper head and neck support, and adjusting the head for accurate coil placement on the target area.
Treatment process begins with initial titration, starting at a lower intensity and
gradually increasing while monitoring the patient’s responses (e.g., motor evoked
potentials, sensations). Stimulation is then applied according to the protocol (continuous or intermittent). Continuous monitoring of vital signs, neurological status,
and patient comfort is essential throughout the session.
Posttreatment procedure involves reevaluating the patient to assess immediate
effects or side effects, including a brief neurological examination and recording

1 Transcranial Magnetic Stimulation
subjective experiences. Detailed treatment records should be maintained, documenting patient information, treatment parameters (e.g., coil type, intensity, frequency), responses during treatment, and posttreatment evaluations for future
reference.
7
1.2.2 TMS Treatment Precautions
1.2.2.1 Seizure Risk
To minimize seizure risk during TMS, patients with a history of epilepsy or seizure
disorders must undergo thorough screening, including seizure type, frequency, and
current antiepileptic treatment. Stimulation parameters should be carefully managed, limiting frequency (usually <20–30Hz), titrating intensity, and controlling
pulse count and duration to reduce seizure risk.
1.2.2.2 Scalp andHead Discomfort
Scalp and head discomfort are common during TMS.Mild scalp pain may result
from coil pressure, magnetic eld effects, or muscle contractions, and can be
relieved by adjusting the coil or reducing intensity. Headaches or migraines may
occur, potentially due to changes in cerebral blood ow, and should be managed
with medical guidelines.
1.2.2.3 Other Precautions
Other precautions include screening for metallic implants, particularly ferromagnetic materials, as they may interact with the magnetic eld. TMS during pregnancy
and lactation is generally avoided due to insufcient safety data, and should only be
considered with a multidisciplinary assessment if benets outweigh risks.
1.3 Principle andMechanism
1.3.1 Alteration ofMembrane Potential andCortical Excitability
1.3.1.1 Membrane Potential Alterations
TMS-induced currents modulate neuronal membrane potential [20]. Depolarization
elevates the membrane potential to threshold, initiating an action potential and
enhancing neuronal excitability. Conversely, hyperpolarization lowers the membrane potential, reducing the likelihood of reaching threshold and decreasing neuronal excitability.
1.3.1.2 Role ofIon Channels
Ion channels on the neuronal membrane are pivotal in modulating excitability
changes induced by TMS.Voltage-gated sodium channels (Nav) facilitate action
potential generation upon depolarization, allowing sodium inux [21]. In GABAergic neurons, TMS may inuence chloride channels, such as the GABAA receptor

8
complex, altering inhibitory functions and potentially modulating excitatory neuronal activity through GABAergic regulation [22].
Y. Liu and S. Hu
1.3.2 Altering Synaptic Plasticity andCortical
Functional Connectivity
1.3.2.1 Long-Term Potentiation (LTP) andLong-Term
Depression (LTD)
TMS can induce long-term potentiation (LTP) or long-term depression (LTD) at
synapses between cortical neurons, depending on the stimulation parameters. Highfrequency TMS enhances glutamate release, activating ionotropic glutamate receptors (e.g., AMPA, NMDA), leading to calcium inux and the activation of
intracellular signaling pathways, such as CaMKII.This results in the insertion of
AMPA receptors, enhancing synaptic transmission and generating LTP [23, 24].
Conversely, low-frequency TMS may reduce glutamate release or alter its timing,
modulate GABA release, and induce hyperpolarization or AMPA receptor internalization, reducing synaptic efciency and promoting LTD [25, 26]. TMS may modulate the morphology and density of neuronal dendritic spines, which are integral to
synaptic plasticity. These structural changes can lead to an increased complexity of
neuronal connectivity, thereby promoting enhanced brain plasticity, as demonstrated in various studies [27, 28].
1.3.2.2 Regulation ofLocal Neural Circuits andLong-Distance
Brain Connectivity
TMS can regulate local neural circuits within the cerebral cortex by modulating the
strength and synchrony of neuronal connections [29]. Through adjustments in the
excitatory and inhibitory balance, TMS alters the information processing capacity
of these circuits. Additionally, TMS can impact long-distance brain connectivity,
inuencing distant brain regions by transmitting signals via white matter tracts,
such as the corpus callosum, thereby affecting global brain network activity [30].
1.4 Effect Factors
1.4.1 Stimulation Frequency
1.4.1.1 Frequency Classification Related toPhysiological Effects
Stimulation frequency in TMS refers to the number of magnetic stimulation pulses
applied per unit time (usually per second), with the unit being hertz (Hz). It is a
crucial parameter characterizing the rhythm of TMS stimulation and reects the
temporal sequence properties of magnetic stimulation. Low-frequency stimulation
(usually <1Hz) inhibits neuronal activity by hyperpolarizing the membrane, reducing excitatory neurotransmitter release and promoting inhibitory neurotransmitter
release, akin to long-term depression (LTD). In contrast, high-frequency stimulation
Соседние файлы в папке Библиотека им академика М.И. Перельмана
